Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.

Type
Private
HQ
San Francisco, US
Founded
2013
Alector was founded in 2013 and is headquartered in San Francisco, US
Report incorrect company information

Key People/Management at Alector

Arnon Rosenthal

Arnon Rosenthal

CEO
Robert paul

Robert paul

Chief Medical Officer
Robert king

Robert king

Chief Development Officer
Sabah Oney

Sabah Oney

Chief Business Officer
Tina Schwabe

Tina Schwabe

Director of Immuno-Neurology
Hua Long

Hua Long

Director of Pre-Clinical Research
Show more

Alector Office Locations

Alector has offices in South San Francisco and San Francisco
San Francisco, US (HQ)
953 Indiana St
Show all (2)
Report incorrect company information

Alector Financials and Metrics

Summary Metrics

Alector's latest funding round in July 2018 was reported to be $133 m. In total, Alector has raised $194.5 m
Show all financial metrics
Report incorrect company information

Alector News and Updates

A company that's taking a new approach to tackling Alzheimer's is moving into human trials after raising $133 million

Biotech startup Alector is getting ready to put its first batch of neurodegenerative drugs into humans after raising an additional $133 million.  Alector is developing treatments that harness the body's immune system to tackle conditions like Alzheimer's, and other forms of dementia. The plan is t…

Alzheimer’s Disease Diagnostic Market 2022 Forecasts by Top 10+ Players Treventis Corporation (US), Neuro-Bio Ltd (UK), Cognition Therapeutics Inc. (US) and Others

Global Alzheimer’s Disease Diagnostic Market Information, by Type (Early-onset Alzheimer's, Late-onset Alzheimer's, Familial Alzheimer's disease), by Diagnostic test (Genetic testing, Neurological exam, Mini-mental state exam (MMSE), Brain imaging and others), by End Users (Clinics, Hospitals, Diagn…
Report incorrect company information

Alector Company Life and Culture

Report incorrect company information